Safety, Risks, and the 2026 FDA Milestone
A major shift occurred in late 2025/early 2026 when the FDA initiated the removal of certain "Black Box" warnings from several hormone products. This was based on 20 years of data showing that when initiated early and used appropriately, the risks of cardiovascular disease and breast cancer are significantly lower than previously feared.
However, BHRT is not without risk. Potential side effects can include bloating, acne, breast tenderness, or mood swings as the body adjusts. It is contraindicated for individuals with a history of certain hormone-sensitive cancers, undiagnosed vaginal bleeding, or high risk for blood clots. The 2026 standard of care requires regular monitoring of hormone levels via blood or saliva tests to ensure the "lowest effective dose" is being used.
